Survey 2 is now live – here's where we're at
The PASSPORT PSP Priority Setting Partnership has launched Survey 2, inviting clinicians, patients and families worldwide to help identify the Top 10 research priorities for paediatric sepsis. Takes 2 to 3 minutes to complete.
When we launched Survey 1, we asked the global paediatric sepsis community to share the research questions that matter most to them.
More than 600 surveys were completed by clinicians, patients and families across 62 countries, generating over 1,350 research questions. Every single one has been reviewed against published evidence, and a refined shortlist is now ready.
That shortlist is the basis for Survey 2, which is now open. We're asking the community to review it and pick their Top 10 — the questions they believe most urgently need answers. It takes 2 to 3 minutes and is open to clinicians, patients and families globally.
If you haven't taken the survey yet, we'd love to hear from you. And if you have, please share it with colleagues, networks and communities who might want to have their say.
Shaping the Future of Paediatric Sepsis Research
The Paediatric Sepsis Research Priority Survey is inviting global participation to help identify key research areas in paediatric sepsis. This initiative aims to shape future studies and improve outcomes for children affected by sepsis worldwide. By contributing, patients, parents, carers and health care professionals can influence the direction of critical research to better understand and treat this serious condition in children.
Every year, an estimated 25.2 million children worldwide are diagnosed with sepsis — with 3.4 million tragically losing their lives. Sepsis remains one of the most urgent and devastating health challenges facing children globally.
To change this, a new initiative is underway: the Paediatric Adaptive Sepsis Platform Trial (PASSPORT). This groundbreaking trial is being designed to test multiple treatments for paediatric sepsis under a single, adaptive platform. By using cutting-edge trial methods, PASSPORT will:
Evaluate several treatments at the same time
Adapt based on results in real time, so children always receive the best evidence-based care
Accelerate the discovery of effective therapies for critically ill children
The trial will begin in 2027, enrolling children aged 1 month to 18 years across Australia and New Zealand, before expanding to include sites around the world.
Hear from members of our PSP Steering Group:
But what research questions are most important?
Before PASSPORT begins, we want to ensure that the research focuses on the questions that matter most to those affected by sepsis: patients, parents and carers, and health care professionals.
That’s why we’re partnering with the James Lind Alliance to run a Research Priority Survey. The survey will identify the top unanswered questions about paediatric sepsis and guide the PASSPORT trial to address them.
By taking part, you can help shape the future of sepsis research — ensuring the trial delivers answers that will truly improve outcomes for children.
Get involved
📅 The Research Priority Survey launches just in time for World Sepsis Day — Saturday 13 September.
Follow us on socials and share the survey
Together, we can reduce the global burden of paediatric sepsis and save young lives.